中源协和细胞基因工程股份有限公司（以下简称"公司"）十一届二十一 次董事会会议于 2025 年 8 月 27 日以通讯表决方式召开。会议通知和会议资料 已于 2025 年 8 月 16 日以电子邮件形式向全体董事发出。应出席会议的董事 9 名，实际出席会议的董事 9 名。会议符合《公司法》和《公司章程》的规定， 表决有效。经出席会议的董事认真审议，通过了以下决议： 1、以 9 票赞成、0 票反对、0 票弃权，审议通过了《公司 2025 年半年度报 告》全文及摘要； 证券代码：600645 证券简称：中源协和 公告编号：2025-033 中源协和细胞基因工程股份有限公司 十一届二十一次董事会会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本议案经公司第十一届董事会审计委员会 2025 年第五次会议审议通过。 《公司 2025 年半年度报告》全文及摘要详见上海证券交易所网站 www.sse.com.cn。 2、以 9 票赞成、0 票反对、0 票弃权，审议通过了《公司 2025 年半年度募 集资金存放与实际使用情况的专 ...

[Definitions](index=4&type=section&id=%E7%AC%AC%E4%B8%80%E8%8A%82%20%E9%87%8A%E4%B9%89) [Definitions of Common Terms](index=4&type=section&id=%E5%B8%B8%E7%94%A8%E8%AF%8D%E8%AF%AD%E9%87%8A%E4%B9%89) This chapter defines key terms, regulatory bodies, company entities, biotechnology terms, and reporting periods for clear understanding of the report content - The report defines key entities and professional terms such as **China Securities Regulatory Commission (CSRC)**, **the Company**, **Jiadao Success**, **Deyuan Health**, **OriGene Technologies, Inc.**, **In Vitro Diagnostics (IVD)**, **Mesenchymal Stem Cells (MSC)**, **induced Pluripotent Stem Cells (iPSC)**, **National Medical Products Administration (NMPA)**, **Center for Drug Evaluation (CDE)**, and **Food and Drug Administration (FDA)**[15](index=15&type=chunk) [Company Profile and Key Financial Indicators](index=4&type=section&id=%E7%AC%AC%E4%BA%8C%E8%8A%82%20%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B%E5%92%8C%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) This section provides an overview of the company's basic information and key financial performance indicators [Company Information](index=4&type=section&id=%E4%B8%80%E3%80%81%E5%85%AC%E5%8F%B8%E4%BF%A1%E6%81%AF) This section presents the company's fundamental registration details, including its Chinese name, abbreviation, foreign name, and legal representative Company Basic Information | Metric | Content | | :--- | :--- | | Chinese Name | 中源协和细胞基因工程股份有限公司 | | Chinese Abbreviation | 中源协和 | | Foreign Name | VCANBIO CELL & GENE ENGINEERING CORP., LTD | | Legal Representative | WANG HONGQI（王洪琦） | [Contacts and Contact Information](index=4&type=section&id=%E4%BA%8C%E3%80%81%E8%81%94%E7%B3%BB%E4%BA%BA%E5%92%8C%E8%81%94%E7%B3%BB%E6%96%B9%E5%BC%8F) This section provides contact information for the company's Board Secretary and Securities Affairs Representative, including names, addresses, phone numbers, faxes, and email addresses Contact Information | Position | Name | Contact Address | Phone | Fax | Email | | :--- | :--- | :--- | :--- | :--- | :--- | | Board Secretary | 陈轶青 | 天津市滨海高新区华苑产业区梅苑路12号 | 022-58617160 | 022-58617161 | zhongyuanxiehe@vcanbio.com | | Securities Affairs Representative | 张奋 | 天津市滨海高新区华苑产业区梅苑路12号 | 022-58617160 | 022-58617161 | zhongyuanxiehe@vcanbio.com | [Brief Introduction to Changes in Basic Information](index=5&type=section&id=%E4%B8%89%E3%80%81%E5%9F%BA%E6%9C%AC%E6%83%85%E5%86%B5%E5%8F%98%E6%9B%B4%E7%AE%80%E4%BB%8B) This section outlines the company's current registered and office addresses, noting that historical changes are available in company announcements - The company's registered address is Floor 2, Building A, No. 12 Meiyuan Road, Huayuan Industrial Zone, Binhai High-tech Zone, Tianjin, and its office address is No. 12 Meiyuan Road, Huayuan Industrial Zone, Binhai High-tech Zone, Tianjin[17](index=17&type=chunk) [Brief Introduction to Changes in Information Disclosure and Document Custody Locations](index=5&type=section&id=%E5%9B%9B%E3%80%81%E4%BF%A1%E6%81%AF%E6%8A%AB%E9%9C%B2%E5%8F%8A%E5%A4%87%E7%BD%AE%E5%9C%B0%E7%82%B9%E5%8F%98%E6%9B%B4%E6%83%85%E5%86%B5%E7%AE%80%E4%BB%8B) This section specifies the company's designated newspapers for information disclosure, the website for report publication, and the location for report availability - The company designates "China Securities Journal", "Shanghai Securities News", and "Securities Times" as its information disclosure newspapers, with the semi-annual report published on www.sse.com.cn and available at No. 12 Meiyuan Road, Huayuan Industrial Zone, Binhai High-tech Zone, Tianjin[18](index=18&type=chunk) [Overview of Company Shares](index=5&type=section&id=%E4%BA%94%E3%80%81%E5%85%AC%E5%8F%B8%E8%82%A1%E7%A5%A8%E7%AE%80%E5%86%B5) This section provides a brief overview of the company's A-share stock, including its listing exchange, abbreviation, and code Company Stock Overview | Share Type | Listing Exchange | Stock Abbreviation | Stock Code | | :--- | :--- | :--- | :--- | | A股 | 上海证券交易所 | 中源协和 | 600645 | [Company's Key Accounting Data and Financial Indicators](index=5&type=section&id=%E4%B8%83%E3%80%81%E5%85%AC%E5%8F%B8%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) This section presents the company's key accounting data and financial indicators for the current and prior periods, explaining the reasons for profit decline Key Accounting Data (Unit: yuan) | Item | Current Period (Jan-Jun) | Prior Period | Change from Prior Period (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 716,369,723.52 | 802,285,328.09 | -10.71 | | Total Profit | 74,744,079.80 | 114,140,321.07 | -34.52 | | Net Profit Attributable to Shareholders | 57,770,452.54 | 85,185,087.67 | -32.18 | | Net Cash Flow from Operating Activities | 123,036,717.91 | 98,635,675.90 | 24.74 | Key Financial Indicators (Unit: yuan/share) | Item | Current Period (Jan-Jun) | Prior Period | Change from Prior Period (%) | | :--- | :--- | :--- | :--- | | Basic EPS | 0.13 | 0.18 | -27.78 | | Diluted EPS | 0.13 | 0.18 | -27.78 | | Basic EPS after Non-recurring Gain/Loss | 0.12 | 0.18 | -33.33 | | Weighted Avg. ROE (%) | 1.59 | 2.32 | 减少0.73个百分点 | - The company's total profit, net profit attributable to shareholders, and net profit attributable to shareholders after non-recurring gain/loss decreased from the prior period, primarily due to a decline in reagent segment revenue and a year-on-year decrease in net profit[23](index=23&type=chunk) [Non-recurring Gain/Loss Items and Amounts](index=6&type=section&id=%E4%B9%9D%E3%80%81%E9%9D%9E%E7%BB%8F%E5%B8%B8%E6%80%A7%E6%8D%9F%E7%9B%8A%E9%A1%B9%E7%9B%AE%E5%92%8C%E9%87%91%E9%A2%9D) This section details the non-recurring gain/loss items and their amounts for the reporting period, totaling **3.88 million yuan** Non-recurring Gain/Loss Items and Amounts (Unit: yuan) | Non-recurring Gain/Loss Item | Amount | | :--- | :--- | | Gain/Loss on Disposal of Non-current Assets | -332,722.36 | | Government Grants Recognized in Current P&L | 1,163,733.71 | | Fair Value Change G/L & Disposal G/L from Fin. Assets/Liabilities | 5,000,290.13 | | Reversal of Impairment for Receivables Individually Assessed | 351,418.58 | | Other Non-operating Income & Expenses | -223,827.70 | | Other Non-recurring G/L Items | -1,543,812.26 | | Less: Income Tax Impact | 370,288.98 | | Minority Interest Impact (After Tax) | 166,023.23 | | **Total** | **

证券之星消息，8月20日医疗器械板块较上一交易日上涨0.06%，济民健康领涨。当日上证指数报收于 3766.21，上涨1.04%。深证成指报收于11926.74，上涨0.89%。医疗器械板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 603222 | 济民健康 | 11.86 | 10.02% | 164.39万 | | 18.28亿 | | 300642 | 透景生命 | 24.81 | 7.45% | 35.17万 | | 8.65 Z | | 688581 | 安杰思 | 87.93 | 6.07% | 2.57万 | | 2.20亿 | | 301093 | 华兰股份 | 34.04 | 4.58% | 13.19万 | | 4.45亿 | | 600645 | 中源协和 | 29.66 | 3.27% | 23.37万 | | ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医疗器械板块主力资金净流出6.22亿元，游资资金净流入8454.45万元，散户资 金净流入5.38亿元。医疗器械板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300049 | 福瑞股份 | 1.46 Z | 11.88% | -1.05 Z | -8.52% | -4138.97万 | -3.36% | | 300003 | 乐普医疗 | 1.21 Z | 7.97% | -5108.00万 | -3.37% | -6962.47万 | -4.59% | | 600645 | 中源协和 | 9348.49万 | 9.75% | -3949.64万 | -4.12% | -5398.85万 | -5.63% | | 688271 | 联影医疗 | ...

Group 1 - The core announcement is that the company's wholly-owned subsidiary, Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., has received a notice of acceptance for the clinical trial application of VUM02 injection from the National Medical Products Administration (NMPA) [1] - VUM02 injection is a cryopreserved cell preparation developed by the company, derived from umbilical cord mesenchymal stem cells (UC-MSC), aimed at treating post-pneumonia pulmonary fibrosis [2] - As of June 2025, the total R&D investment for the related project has reached RMB 22.33 million [2]

Core Viewpoint - Zhongyuan Union announced that its wholly-owned subsidiary, Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., received the acceptance notice for the clinical trial application of VUM02 injection from the National Medical Products Administration (NMPA) on August 1, 2025 [1] Group 1 - The clinical trial application for VUM02 injection has been officially accepted by the NMPA [1]

Group 1 - Weihai Guangtai reported a net profit of 83.32 million yuan for the first half of 2025, a year-on-year decrease of 22.41%, while total revenue reached 1.425 billion yuan, an increase of 10.91% [1] - Haowei Group expects a net profit increase of 39.43% to 49.67% for the first half of 2025, estimating a profit range of 1.906 billion to 2.046 billion yuan [1] - Tengda Construction won a bid for a project worth 118 million yuan, with a construction period of 500 calendar days [1] Group 2 - Shanda Power plans to use up to 520 million yuan of idle raised funds for cash management, investing in safe and liquid products with a term not exceeding 12 months [3] - Rundu Co., Ltd. received approval for the listing application of its chemical raw material drug, which is suitable for surgical treatment in adults and children over one month old [4] - Zhongyuan Qihua's subsidiary's clinical trial application for a drug aimed at treating pulmonary fibrosis has been accepted [4] Group 3 - Shanghai Xiba plans to establish a joint venture with Yuyuan Rare Earth, focusing on advanced materials for lithium-ion solid-state batteries, with a registered capital of 200 million yuan [6] - Aorite's senior management plans to reduce their holdings by up to 62,500 shares, accounting for 0.02% of the company's total equity [7] - Yipin Hong's subsidiary's clinical trial application for a new oral drug for endometriosis has been accepted [8] Group 4 - Haya Pharmaceutical plans to lease idle assets covering 22,671.39 square meters for a period of 10 years [9] - Southern Precision Engineering applied for a credit limit of 50 million yuan from a bank for operational purposes [11] - Jindawei's subsidiary established a joint venture with a registered capital of 5 million yuan, focusing on the sale of food additives and health products [12] Group 5 - Gaode Infrared signed a product order contract worth 307 million yuan, expected to account for 11.46% of the company's audited revenue for 2024 [13] - Xichang Electric will implement a low valley electricity price policy starting September 1, 2025, which is expected to reduce net profit by approximately 5.55 million yuan [14] - Huyou Pharmaceutical's first subject has been dosed in a Phase I clinical trial for a drug targeting advanced solid tumors [16] Group 6 - Chuanheng Co., Ltd. received a patent for a dust removal system in mining operations [17] - Spring Wind Power's application for issuing convertible bonds has been accepted by the Shanghai Stock Exchange [18] - Liuyao Group plans to repurchase shares worth between 100 million and 200 million yuan [19] Group 7 - Baiyun Electric has obtained a commitment letter for a stock repurchase loan of up to 18 million yuan [20] - Tonghe Pharmaceutical received a patent for a method of preparing an intermediate for a migraine treatment drug [21] - Tainkang's subsidiary's Phase II clinical trial for a drug for vitiligo has shown significant efficacy and safety [23] Group 8 - Yuhua Tian's secretary and deputy general manager resigned for personal reasons [24] - Heizhima's controlling shareholder is planning a change in control, leading to a temporary suspension of stock trading [25] - Keda Li's subsidiary completed a capital increase, raising its registered capital to 700 million yuan [26] Group 9 - Fangda Special Steel's shareholder plans to reduce holdings by up to 1% of the company's shares [28] - ST Pava's director is under investigation for alleged embezzlement, but the company's operations remain normal [29] - Jiachuan Video's controlling shareholder is planning a change in control, resulting in a temporary stock suspension [32] Group 10 - Danhua Technology will change its stock name to Jinmei Technology starting August 7, 2025, due to a relocation of its registered office [33] - Morning Wind Technology's shareholder plans to reduce holdings by up to 1% of the company's shares [34] - Leshan Electric will adjust residential gas prices starting September 1, 2025, which is expected to increase gross profit by approximately 2.7 million yuan [35] Group 11 - SAIC Motor reported a total vehicle sales of 337,500 units in July 2025, a year-on-year increase of 34.22%, with significant growth in new energy vehicle sales [36] - LIGONG Navigation's shareholders plan to reduce holdings by up to 3% of the company's shares [37] - United Imaging's employee stock ownership platform plans to reduce holdings by up to 1.62% of the company's shares [38] Group 12 - Beiqi Blue Valley's subsidiary reported a 6.38% decline in sales in July 2025 [39] - Watson Bio's clinical research application for an mRNA vaccine has been accepted [40]

证券代码：600645 证券简称：中源协和 公告编号：2025-032 中源协和细胞基因工程股份有限公司（以下简称"公司"）全资子公司武汉 光谷中源药业有限公司于 2025 年 8 月 1 日取得国家药品监督管理局药品审评中 心（CDE）签发的关于 VUM02 注射液临床试验申请《受理通知书》，受理号为 CXSL2500651。现对有关信息公告如下： 中源协和细胞基因工程股份有限公司 关于全资子公司药品临床试验申请取得受理通知书 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、药品基本信息 药品名称：VUM02 注射液 剂型：注射剂 规格：5E7 个细胞（10 mL）/袋 注册分类：治疗用生物制品 1 类 申请事项：境内生产药品注册临床试验 申请人：武汉光谷中源药业有限公司 受理号：CXSL2500651 二○二五年八月五日 VUM02 注射液（人脐带源间充质基质细胞注射液）是我司自主研发的冷冻 保存型细胞制剂，是由经筛选的健康新生儿脐带组织通过体外分离、扩增、收获、 冻存后制备的人脐带源间充质基质细胞（UC-MS ...

Core Viewpoint - Zhongyuan Union (600645.SH) announced that its wholly-owned subsidiary, Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., received the Clinical Trial Application Acceptance Notice from the National Medical Products Administration (NMPA) for VUM02 injection on August 1, 2025, indicating progress in the development of this new drug [1] Group 1 - The VUM02 injection is a cryopreserved cell preparation developed independently by the company, derived from selected healthy newborn umbilical cord tissue [1] - The clinical trial aims to expand the indications for VUM02 injection to include the treatment of pulmonary fibrosis following pneumonia [1]

Core Viewpoint - Zhongyuan Union (600645.SH) announced that its wholly-owned subsidiary, Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., received the Clinical Trial Application Acceptance Notice from the National Medical Products Administration (NMPA) for VUM02 injection on August 1, 2025, marking a significant step in the development of a new treatment for post-pneumonia pulmonary fibrosis [1] Group 1 - VUM02 injection is an autologous cryopreserved cell preparation derived from umbilical cord mesenchymal stem cells (UC-MSC) obtained from healthy newborns [1] - The clinical application aims to treat post-pneumonia pulmonary fibrosis, a condition for which no similar cell therapies are currently available globally [1] - The development of VUM02 is supported by previous clinical research data from studies on COVID-19 and idiopathic pulmonary fibrosis [1]